Unmet needs in the treatment of idiopathic pulmonary fibrosis―insights from patient chart review in five European countries

BACKGROUND: Two antifibrotic drugs, pirfenidone and nintedanib, are approved by the European Medicines Agency and the US Food and Drug Administration for the treatment of idiopathic pulmonary fibrosis (IPF). In this analysis, treatment patterns of European patients with IPF were investigated to unde...

Descripción completa

Detalles Bibliográficos
Autores principales: Maher, Toby M., Molina-Molina, Maria, Russell, Anne-Marie, Bonella, Francesco, Jouneau, Stéphane, Ripamonti, Elena, Axmann, Judit, Vancheri, Carlo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5602932/
https://www.ncbi.nlm.nih.gov/pubmed/28915874
http://dx.doi.org/10.1186/s12890-017-0468-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5602932/
https://www.ncbi.nlm.nih.gov/pubmed/28915874
http://dx.doi.org/10.1186/s12890-017-0468-5

Ejemplares similares